Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boisen Matthew L, Hartnett Jessica N, Shaffer Jeffrey G, Goba Augustine, Momoh Mambu, Sandi John Demby, Fullah Mohamed, Nelson Diana K S, Bush Duane J, Rowland Megan M, Heinrich Megan L, Koval Anatoliy P, Cross Robert W, Barnes Kayla G, Lachenauer Anna E, Lin Aaron E, Nekoui Mahan, Kotliar Dylan, Winnicki Sarah M, Siddle Katherine J, Gbakie Michael, Fonnie Mbalu, Koroma Veronica J, Kanneh Lansana, Kulakosky Peter C, Hastie Kathryn M, Wilson Russell B, Andersen Kristian G, Folarin Onikepe O, Happi Christian T, Sabeti Pardis C, Geisbert Thomas W, Saphire Erica Ollmann, Khan S Humarr, Grant Donald S, Schieffelin John S, Branco Luis M, Garry Robert F
Аннотация
Lassa fever, a hemorrhagic fever caused by Lassa virus (LASV), is endemic in West Africa. It is difficult to distinguish febrile illnesses that are common in West Africa from Lassa fever based solely on a patient's clinical presentation. The field performance of recombinant antigen-based Lassa fever immunoassays was compared to that of quantitative polymerase chain assays (qPCRs) using samples from subjects meeting the case definition of Lassa fever presenting to Kenema Government Hospital in Sierra Leone. The recombinant Lassa virus (ReLASV) enzyme-linked immunosorbant assay (ELISA) for detection of viral antigen in blood performed with 95% sensitivity and 97% specificity using a diagnostic standard that combined results of the immunoassays and qPCR. The ReLASV rapid diagnostic test (RDT), a lateral flow immunoassay based on paired monoclonal antibodies to the Josiah strain of LASV (lineage IV), performed with 90% sensitivity and 100% specificity. ReLASV immunoassays performed better than the most robust qPCR currently available, which had 82% sensitivity and 95% specificity. The performance characteristics of recombinant antigen-based Lassa virus immunoassays indicate that they can aid in the diagnosis of LASV Infection and inform the clinical management of Lassa fever patients.